Key result
SCAI stage B cardiogenic shock shows rapid progression, with high rates of MCS and mortality.
Why the study?
The 2019 SCAI shock staging system requires additional large-scale validation studies to confirm its validity in clinical practice and research.
Case Report (n=4)
SCAI stage B progression may warrant intensified monitoring; hypothesis-generating for dynamic staging utility in larger cohorts.
The 2019 SCAI shock staging system is a valid risk stratification tool in hemodynamically unstable patients. Shock stage is a strong predictor of short-term mortality and its daily re-assessment may guide the escalation or de-escalation of therapy. Additional large-scale validation studies are needed to confirm the new SCAI shock staging system's validity in clinical practice and research.
No takes yet. Share an insight, caveat, or question.
Nicolas et al. (2020) conducted a case report in Cardiogenic Shock (n=4). SCAI Stage B Cardiogenic Shock was evaluated. SCAI stage B cardiogenic shock exhibited dynamic progression in a 4-patient case series, where all 4 patients required mechanical circulatory support and 3 ultimately died due to multiorgan failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: